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Background: Carotid artery stenosis is an important risk factor and etiology of stroke. Carotid endarterectomy (CEA) is
the gold standard for the treatment of carotid artery stenosis; however, there are potential benefits to adopting the use of
carotid artery stenting (CAS) with protection devices. A number of large protected CAS (PCAS) trials are underway, but
final results are still several years away. In the interim, numerous PCAS studies have recently been published, and the aim
of this study was to combine the published results and examine the outcomes and safety of PCAS.
Methods: Electronic, manual, and bibliographic searches of PubMed and PreMedline were conducted. Proportion
differences were calculated for the periprocedural (30-day) outcomes of any stroke and any stroke or death.
Results: More than 400 articles were identified. Only 26 studies met the inclusion criteria, resulting in the inclusion of
2,992 patients treated with PCAS. Within this patient group, the pooled perioperative PCAS rate of any type of stroke
was 2.4% 0.3% (95% confidence interval [CI]). The 30-dayminor stroke rate was 1.1% 0.2% (95%CI), and the 30-day
major stroke rate was 0.6%  0.2% (95% CI). The 30-day mortality rate was 0.9%  0.4% (95% CI).
Conclusion: This study demonstrates relatively low rates of reported perioperative adverse events in PCAS. Selective use of
PCAS to treat carotid artery stenosis in those at highest risk for surgical complications is appropriate until the randomized
trials of CEA vs PCAS provide concurrent short- and long-term outcome data. (J Vasc Surg 2005;42:1094–1100.)Stroke ranks as the third most common cause of North
American mortality and represents the leading cause of long-
term disability in the United States, with a high concomitant
financial burden.1,2 Carotid artery stenosis accounts for ap-
proximately 20% of all strokes.3 Among the management
options are maximal medical risk reduction and surgical alter-
natives, including carotid endarterectomy (CEA) and carotid
angioplasty and stenting (CAS).4 CEA was established as the
gold standard for management of high-grade symptomatic
carotid stenosis by the randomized North American Symp-
tomatic Endarterectomy (NASCET) and the European Ca-
rotid Surgery Trial (ECST).5-7 The ECST has provided new
randomized evidence for surgical therapy for asymptomatic
stenosis.
CEA, however, remains a surgical procedure with sig-
nificant intraoperative and postoperative risks.1 The risks of
surgery can be higher in those with severe hypertension or
coronary, pulmonary, peripheral vascular, or renal dis-
ease.4,8 Complications of CEA include stroke, cranial or
cervical nerve injuries (reported to occur in 7.6% to 27% of
CEA patients), myocardial infarction, wound hematoma,
intracerebral hemorrhage, seizures, and death.1,9 Eco-
nomic studies have shown that CEA is superior to CAS in
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doi:10.1016/j.jvs.2005.08.020terms of cost savings10; thus, CEA has remained the stan-
dard of care with respect to stroke prevention.
CAS was pioneered in 1977 and has recently experi-
enced rapid growth due to technologic advances.11,12
Stents are used in conjunction with angioplasty to preserve
vessel patency.13 Embolization during stent placement is
the most important complication of CAS and can be rec-
ognized by using Doppler scans and magnetic resonance
image monitoring, which have demonstrated the release of
significant volumes of macro- and microemboli during
CAS.14 Studies of human carotid plaques demonstrate
release of emboli during all steps of CAS and in greater
number than in CEA.15-18
Stents do not appear to cause the liberation of further
emboli after placement. Protected carotid angioplasty with
stenting (PCAS) uses cerebral protection devices that
promise enhancement of CAS by lowering the incidence of
neurologic complications related to embolization of ca-
rotid plaque debris into the cerebral circulation while either
temporarily obstructing or simultaneously permitting cere-
bral perfusion.19-26 PCAS disadvantages include interrup-
tion of blood flow during cerebral protection, inability to
perform angiograms during the procedure, difficulties
crossing tight or tortuous lesions, suboptimal emboli cap-
ture capacity, and vessel dissection.26
A number of cerebral protection devices have been
approved for use and initial results are promising, showing
a reduction in CAS-related morbidity and mortality.1,27,28
The use of cerebral protection devices , superior stents, and
incremental clinical experience are thought to have lowered
the risks associated with CAS and have also widened the
spectrum of carotid diseases that may be treated with
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to CEA in many centers, although some practitioners con-
tinue to perform CAS without cerebral protection devices
due to a potential increase in both technical complexity and
the time in which the catheter is used during the PCAS
procedure.30,31
For many practitioners, PCAS is considered an accept-
able alternative to CEA for high-surgical-risk patients with
high-grade stenosis, such as those with postsurgical reste-
nosis, synchronous carotid and coronary artery disease, or
high lesions not amenable to surgical access, such as those
located at the skull base.4,32-36 Although it has been sug-
gested that PCAS is an acceptable approach in these cases,
study data are in conflict: some report relatively major
combined post-CAS death and stroke rates of 4.7% to 6.5%
compared with the CEA related risk of 0.6%.9,32,38 The
Carotid and Vertebral Artery Transluminal Angioplasty
study (CAVATAS), designed to evaluate the risks and
benefits of angioplasty, reported that CAS had similar ma-
jor risks and efficacy in a 3-year follow-up compared with
CEA.37
Finally, CAS is not without complications, including
severe bradycardia, groin hematoma, and postprocedure
hemodynamic instability. Also needed is meticulous tech-
nical expertise in performing the procedure.13,20,34,39
Thus PCAS is challenging surgical therapy. Appropri-
ately powered, randomized trials of CEA compared with
PCAS are underway in average-risk patients (CREST,
EVA3S, and CABERNET); however, it will be some time
until the results of these trials are released.26,31,40 Overall,
the current body of evidence has been deemed insufficient
for determining whether PCAS is a convincingly feasible
and safe alternative to CEA.31
Meta-analyses and systematic reviews may be viewed as
complements to randomized controlled trials until the
appropriate randomized data is released.41 One systematic
review, published in 2003, pooled results from CAS and
PCAS studies conducted between 1996 and 2002.30,42
The aim of the systematic review reported here was to pool
the most current results to generate an adequately powered
study to determine the current feasibility and safety of
PCAS with greater precision.43-49
MATERIALS AND METHODS
Search strategy. An extensive search of the literature
was performed within PubMed (US National Library of
Medicine, Bethesda, Md), PreMedline, and the Cochrane
Register of Controlled Trials (Table I, online only). Search
filters containing combinations of search terms, and
PubMed Clinical Queries with Research Methodology Fil-
ters, were used where possible. The following key words
were used in different permutations: carotid artery, stenosis,
atherosclerosis, angioplasty, stent, cerebral, emboli, and pro-
tection. In addition, bibliographic searches of reference lists
of all core articles (those ultimately included in the review)
were conducted to expose other relevant references as well
as manual searches of five journals. The results include
studies published until December 2004.Study eligibility. Titles, abstracts, or the full texts of
articles were reviewed by using a standardized form to
collate study details (Relevance Test Evaluation Form),
which included six inclusion criteria (Table II, online only).
Studies of all languages were included in the search, in
accordance with findings of researchers pursuing stroke
reviews who found that 8% of studies have the potential for
exclusion if an English language criterion is implemented.50
Studies were included in the review if the following criteria
were fulfilled: (1) the study comprised at least 10 patients,
all of whom received carotid stenting with cerebral protec-
tion, (2) publication date of 2002 or later, (3) primary
study of carotid stenting (ie, no reviews, editorials, letters,
etc), and (4) the number of adverse events (stroke or death)
30 days of the procedure was reported. Additionally, any
type of stent or cerebral protection device could have been
used in the patients’ treatment. In the event that multiple
publications encompassing some of the same patients were
isolated, only the most recent publication was used in the
review. All articles that did not meet the above criteria
were excluded from the review.
Data extraction and statistical analysis. The follow-
ing data were extracted from each of the core studies:
● General: journal, year of publication, institution, treat-
ment date range, number of patients treated, and
number of procedures performed;
● Patient characteristics: mean age, male/female ratio,
symptomatic/asymptomatic ratio;
● Procedural: stent and cerebral protection devices used,
and
● Periprocedural complications 30 days: periproce-
dural technical complications, transient ischemic at-
tacks (TIA), minor and major strokes, death, and total
number of adverse events. With respect to the 30-day
periprocedural complication rates and definitions of
minor and major strokes, all studies used the standard
defined according to the large CEA trial criteria.51,52
The primary purpose of this review was to calculate a
pooled estimate of the perioperative (30-day) adverse event
proportion (any stroke and any stroke or death) of PCAS
studies. This, as well as individual rates for major and minor
strokes and death, were calculated where reported.6,53,54
Two studies did not report a minor stroke rate and were
excluded from that specific analysis,27,55 and two studies
did not report a major stroke rate and were excluded from
that analysis.49,55
We used 2 tests to assess between-study heterogeneity
and the Spearman rank coefficient to assess correlation
between key variables and the primary outcome. In addi-
tion to calculating weighted averages for all adverse treat-
ment outcomes, to account for within-study and between-
study variability, generalized estimating equations were
used to derive a pooled estimate of outcome proportion
and its variance for all adverse treatment outcomes, major
and minor strokes, and death.56 These estimates were
calculated with Excel (Microsoft, Redmond, Wash). P 
.05 was considered statistically significant.
, not
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The literature search isolated 362 articles, of which
26 studies from 9 countries met the inclusion crite-
ria.14,22,27,44-49,55,57-72 At least one study was excluded
because it included 10 patients, and four studies were
excluded because no differentiation was made between
protected and unprotected patient groups.24,73-76
All included studies were considered representative of
patients receiving PCAS. Data abstraction and assessment
was conducted on the 26 core studies, the main character-
istics and 30-day outcomes of which are summarized in
Table III. The number of patients in the core studies upon
whom PCASwas attempted totaled 2,992; and the number
of arteries within which PCAS was attempted totaled
3,091. The studies were conducted between 2002 and
2004, and the mean age of patients was 70.3 years (range,
63 to 76 years). Women comprised 67% of patients (pro-
portion per study, 10% to 84%), and 55% of patients were
symptomatic (proportion per study, 13% to 100%), the
latter defined as presenting with amaurosis fugax, TIAs, or
minor stroke.
At a maximum of 30 days post-PCAS procedure, 2,992
patients had an assessment of postoperative status. Within
this time, among the different studies, the minor stroke rate
was 0% to 6%, the major stroke rate was 0% to 3%, and the
death rate was 0% to 7%. Studies with higher proportions of
Table III. Pooled PCAS study data: study characteristics a
Year Author
Patients
(N)
Treated arteries
(N)
Mean age
(years)
2002 Adami 30 30 72
2002 Al-Mubarak 162 164 68
2002 Angelini 36 38 70.7
2002 Grego 26 26 N/A
2002 Guimaraens 164 194 63
2002 Ohki 31 31 71
2002 Schluter 96 102 68
2002 Whitlow 75 75 67
2003 Bosiers 100 100 72
2003 Castellan 27 29 N/A
2003 Grube 35 37 70
2003 Mudra 100 100 69
2003 Rath 22 30 64
2003 Terada 87 87 73.5
2003 Cemetti 100 104 70.8
2003 Pucillo 22 22 N/A
2003 Cremonesi 442 442 73
2004 McKevitt 103 103 N/A
2004 Powell 69 74 72
2004 Eskandari 53 57 68.8
2004 Henry 242 268 71.2
2004 Chang 19 21 N/A
2004 Yadav 159 159 75.2
2004 Sganzerla 94 100 N/A
2004 Safian 30 30 76
2004 Zahn 668 668 70
Total 2,992 3,091
PCAS, Protected carotid angioplasty with stenting; M/F, male/female; N/Amen (P  .05) and higher proportions of symptomaticpatients did not demonstrate a higher proportion of ad-
verse events (major or minor stroke or death) (P  .05).
The most commonly used stents among those studies
that reported stent types used were Carotid Wallstents
(Boston Scientific; Natick, Mass); and SMART stents and
Palmaz biliary stents (J&J Cordis, New Brunswick, NJ).
The most commonly used cerebral protection devices were
GuardWire (Medtronic; Santa Rosa, Calif), AngioGuard
(J&J Cordis), and EPI FilterWire EX (Boston Scientific)
(Table IV).
For all outcomes, the variability between studies was
not larger than would be expected by chance (heterogene-
ity, P  .05). Given the small between-study variability and
given that the magnitude of treatment effect could be
anticipated to be similar across the range of patients, it was
sensible to proceed with pooling the results.77
The 30-day stroke and death rates in patients treated
with PCAS are summarized in Table V. Higher PCAS
complication rates in symptomatic patients have been re-
ported previously,78 but most core studies did not report
separate rates of complication for symptomatic and asymp-
tomatic patients. In 2,992 PCAS-treated patients, the com-
bined stroke and death rate for symptomatic and asymp-
tomatic patients was 2.4% 0.3% with 95% CI. The 30-day
rate (with 95% CI) for minor stroke was 1.1%  0.2%, for
major stroke was 0.6%  0.2%, and for death was
0-day outcomes
M/F Symp/asymp Minor stroke Major stroke Death
2/8 15/15 0 0 0
8/34 77/85 2 0 2
7/9 18/18 N/A N/A 1
N/A N/A 0 0 0
8/36 146/18 2 0 3
2/9 18/13 N/A 1 1
4/22 N/A 1 1 0
4/21 75/0 0 0 0
0/40 69/31 0 0 0
N/A N/A 0 0 0
8/7 12/23 0 0 0
9/22 41/59 2 0 3
4/8 15/15 1 N/A 1
3/14 70/17 0 1 1
4/26 27/74 2 1 1
N/A N/A 1 0 0
0/92 252/190 4 1 0
N/A 60/43 0 0 0
7/12 26/43 1 0 0
4/19 20/33 0 0 0
4/48 171/97 0 2 1
N/A 12/7 0 0 0
6/53 159/0 9 0 11
N/A N/A 2 2 0
3/27 4/26 0 0 0
2/186 356/312 4 8 2
31 17 27
applicable.nd 3
2
12
2
12
2
7
5
5
2
6
1
7
7
35
5
3
19
10
480.9%  0.4%.
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It is evident by the recent increase in number of studies
of PCAS that CEA as the gold standard of treatment for
carotid stenosis is under challenge by proponents of PCAS.
Although many practitioners believe that a transition to
PCAS should be based on experimental evidence, PCAS
continues to be performed in patients with carotid steno-
sis.15 Indeed, recent reports confirm that surgeons are
moving to PCAS due to its reduced complications com-
pared with CEA, although this efficacy appears to be sur-
mised largely from nonrandomized data or potentially un-
derpowered clinical trial data.57,79
Observational study results are generally considered to
Table IV. Stents and cerebral protection devices used
Year Author Stent(s) used CPD(s) used
2002 Adami N/A 1
2002 Al-Mubarak N/A 2,3,4
2002 Angelini a,d 4
2002 Grego N/A 3,4
2002 Guimaraens N/A N/A
2002 Ohki a 3,4
2002 Schluter a 3
2002 Whitlow a,c,d 3
2003 Bosiers N/A 6
2003 Castellan N/A N/A
2003 Grube N/A 6
2003 Mudra N/A N/A
2003 Rath N/A N/A
2003 Terada a,c,d 7
2003 Cemetti a,d 4
2003 Pucillo N/A N/A
2003 Cremonesi a,b,c,d,e,g 4
2004 McKevitt N/A N/A
2004 Powell a 3
2004 Eskandari N/A 3
2004 Henry a,c,d,h,i,k 3
2004 Chang a 8
2004 Yadav c,j 4,5
2004 Sganzerla N/A N/A
2004 Safian f 9
2004 Zahn N/A N/A
CPD, Cerebal protection device; NA, not applicable.
aCarotid Wallstent (Boston Scientific; Natick, Mass).
bEasy Wallstent (Boston Scientific; Natick, Mass).
cPalmaz (J&J Cordis; New Brunswick, NJ).
dSmart (J&J Cordis; New Brunswick, NJ).
eAcculink (Guidant; Indianapolis, Ind).
fProtégé (Sulzer Medica; Houston, Tex).
gAVE System (Medtronic; Santa Rosa, Calif).
hJoStent (Abbott Vascular; Abbott Park, Ill).
iExpander (Bolton Medical; Barcelona, Spain).
jPrecise (J&J Cordis; New Brunswick, NJ).
kSinus-Flex (Optimed; Ettingen, Germany).
1Parodi (ArteriA; San Francisco, Calif).
2NeuroShield (Mednova Inc.; Galway, Ireland).
3GuardWire (Medtronic; Santa Rosa, Calif).
4Angioguard (J&J Cordis; New Brunswick, NJ).
5Angioguard XP (J&J Cordis; New Brunswick, NJ).
6EPI FilterWire EX (Boston Scientific; Natick, Mass).
7Distal-Balloon Protection System (Kaneka Medix; Osaka, Japan).
8Fogarty Balloon Catheter (Edwards Lifesciences; Irvine, Calif).
9Spider (ev3; Plymouth, Minn).be of lower scientific value relative to those of randomizedcontrolled trials in validating the use of new treatments.
However, systematic reviews of observational data can pro-
vide a source of persuasive evidence to support the contin-
ued use of new approaches, such as the adoption of PCAS
in favor of CEA in the treatment of carotid stenosis.
The results of this review, using the best and latest
possible evidence from the literature, support the reasoning
behind this transition. PCAS was associated with an adverse
event rate of 2.4% in 2,992 patients from 26 studies pub-
lished between 2002 and 2004, which is significantly less
than the adverse event rates reported in large, randomized
trials for both symptomatic and asymptomatic patients
receiving CEA. This event rate is lower that the 6.8%
stroke and death rate of the NASCET trial; however, many
changes in medical therapy have occurred since those data
were generated.
The recent randomized asymptomatic carotid trial
from Europe, which enrolled between April 1993 and
July 2003, noted a 2.8% 30-day stroke and death rate.
Also reported in that trial were 245 CEAs in the nonsur-
gical arm that underwent surgery despite randomization
allocation. Half of the CEAs were converted secondary
to the development of symptoms. The rate of perioper-
ative stroke or death was 4.5% in those individuals.
Among symptomatic patients treated with PCAS there
were 4.1 strokes or deaths per 100 patients.5 Although
practitioners await stronger evidence in the form of
randomized trial data, this study and its resultant obser-
vations represent a source of evidence, buttressed by a
large sample size that demonstrates the relatively low
perioperative rates of adverse events in PCAS-treated
patients. Therefore, the consensus among specialists that
PCAS may be safely used to treat carotid stenosis, but in
conjunction with cerebral protection devices, is support-
ed.80
Despite the encouraging results of this review, a num-
ber of limitations were specific to this analysis, including
potential heterogeneity in patient groups with respect to
the ratio of symptomatic to asymptomatic patients, the
particular types of stents and cerebral protection devices
used, and potential differences in the assessment of certain
risk factors such as the degree of stenosis and complica-
tions. The inclusion of studies in themeta-analysis that have
Table V. Pooled PCAS study data: perioperative adverse
events
Outcome Method Estimate SD 95% CI
All adverse
events
Weighted
average
0.011 0.001 (0.009, 0.013)
GEE 0.024 0.003 (0.018, 0.030)
Minor stroke GEE 0.011 0.001 (0.009, 0.013)
Major stroke GEE 0.006 0.001 (0.004, 0.008)
Death GEE 0.009 0.002 (0.005, 0.013)
PCAS, protected carotid angioplasty with stenting; SD, Standard deviation;
CI, confidence interval; GEE, generalized estimating equations.diverse degrees of stenosis may bias the PCAS group to
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tion, although these data represent the best possible evi-
dence from the literature, the overall quality of the individ-
ual studies that comprised the meta-analysis was not the
highest in terms of evidence-based medicine standards
given the inclusion of case series studies. Differences also
exist between prospective, independently audited and ad-
judicated trial data and those from individual case series.
It is acknowledged that the efficacy of both CEA and
PCAS is highly interventionist-dependent and that standard-
ized procedures, patient selection processes, and periproce-
dural treatment regimens, including the use of enhanced
antiplatelet and lipid-lowering medications, may help
to limit the rate of adverse events and improve out-
comes.20,81,82 Furthermore, the potential for evolving de-
signs in stent and cerebral protection devices (eg, more
friction-resistant catheters) as well as the evolution of the
operator learning curve are likely to enhance the efficacy of
PCAS in the future and reduce the complication rate.83
This may ultimately lead to widespread application of
PCAS among carotid stenosis patients.
This analysis cannot address the cost-effectiveness of
PCAS. Given the added costs associated with PCAS, how-
ever, costs may continue to be a barrier to widespread
implementation of PCAS.
This analysis excluded data from a randomized trial of
58 PCAS patients because of the possibility of potential
duplication of patients already reported in primary series
that was included in the analysis.68,84 (We attempted, but
could not obtain evidence to indicate that patient duplica-
tion between the two studies had not occurred.) A sensi-
tivity analysis that added this trial data to our current
dataset did not alter our point estimates for periprocedural
minor and major stroke or 30-day mortality. A register of
PCAS data was also excluded, which did include data from
primary series (also included), as individual center data
were not subject to peer-review, and patient duplication
would have occurred had the registry data, as a whole, been
included.85
CONCLUSION
This meta-analysis of the most recent published PCAS
data demonstrates a 30-day stroke and death rate of 2.4%.
These data support the need for the randomized, prospec-
tive trials currently underway and justify the selective use of
PCAS in those at higher risk for the current gold standard
therapy, provided it can be performedwith results similar to
those reviewed above.
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December 20051094.e8 Burton and LindsayTable I (online only). Selection criteria and search strategy*
Type of exposure (carotid
stenosis)
Type of outcome
(carotid angioplasty
with CPD device
stents)
Type of patient
(patients with carotid
stenosis patients)
Type of control
(patients treated with
CEA)
Type of study
(randomized controlled
trials preferably)
Inclusion
criteria
● Carotid artery
● Occlusion
● Stenosis
● Angioplasty
● Cerebral protec-
tion
● Stent
● Endovascular
● Filter
● Protection
● Carotid surgery
● Stroke
● Cerebrovascular
disease
Initially:
● Any stenosis
severity
● Any country
● NASCET study
patients (CEA)
● Any type of study
available, conducted
at any point in time
will initially be con-
sidered.
Search strategy
Electronic ● Ovid and free-text
terms for all of the
above in addition to
any related terms
stemming from this
search.
● Search for “related
articles” in PubMed.
● Ovid and free-
text terms for
any of the above.
● Search for “re-
lated articles” in
PubMed.
● Published in any
language.
Manual
search
● 5 journals in the
fields of vascular and
cardiovascular sur-
gery; issues within
the past 6 months:
Annals of Vascular
Surgery, Catheteriza-
tion and Cardiovas-
cular Interventions,
European Journal of
Vascular and Endo-
vascular Surgery,
Stroke, Neurosurgery.
● Published in English
language only.
● Published in peer-
reviewed journals
only.
Other Bibliographic search of
articles from search.
Bibliographic
search of articles
from search.
CPD, Cerebral protection device; CEA, carotid endarterectomy; NASCET, North American Symptomatic Endarterectomy.
*Adapted from Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med 1997;127:380-7.
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Volume 42, Number 6 Burton and Lindsay 1094.e9Table II (online only). Relevance Test Evaluation Form*
Primary Author/Date/Title:
Date of Review:
Selection criteria (indicate with a check mark if each of the following criteria are met:
Primary study of carotid surgery (ie, no reviews, editorials, letters, etc.)
Common or internal carotid stenting only (external carotid artery stenting is excluded)
Publication date of 2002 or later
Any type of cerebral protection device used
At least 10 patients in the study received carotid stenting with cerebral protection
The number of adverse events (stroke, death, or MI) within 30 days of procedure was reported
Action (circle one): (“include” only
if each of the above 6 criteria are met)
Include Exclude
Please list reasons for exclusion (if other than not meeting the above criteria):
MI, Myocardial infarction.
*Adapted from Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med 1997;127:531-7.
